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T
raveling in Vietnam in midsummer aft er 
the hectic days of our World Congress of 
Nephrology in Singapore, I was intrigued 
by local newspapers keeping me informed 
of the dynamics and spread of the feared H5N1 
infl uenza strain. At the Singapore congress, open-
ing speaker Donald Henderson and Nobel laure-
ate Peter Doherty had focused their lectures on 
the threat of a new viral pandemic and had called 
for immediate, coordinated action to study the 
biology of infection and immunity and the devel-
opment of new vaccines and antiviral agents. In 
the Vietnamese newspaper reports and in simi-
lar articles in the scientifi c press,1 attention was 
given to the international army of medical doctors 
and scientists from many countries around the 
globe currently working with local authorities in 
China, Southeast Asia, and Indonesia to monitor 
the spread and genetic drift  of H5N1 and related 
infl uenza strains.
Th eir fi eld work, oft en under diffi  cult circum-
stances, reminded me of the commitment of med-
ical doctors fi ghting in many diff erent countries 
against the health threat posed by war, famine, 
earthquakes, and fl ooding. Among the members 
of this army of MDs one can oft en fi nd nephrolo-
gists who provide emergency dialysis in order to 
prevent death from transient acute renal failure 
resulting from crush syndrome or shock. For this 
purpose, the International Society of Nephrology 
(ISN) has established a renal disaster relief task 
force that is based in Belgium and works in close 
collaboration with Médecins sans Frontières. 
Together they have made major contributions, 
fi ghting earthquake disasters in Armenia, Tur-
key, and, recently, Pakistan and saving hundreds 
of lives.2–4
Diff erent from these two emergencies — one 
infectious, the other calamitous in origin — a 
third, more silent pandemic confronts today’s 
world on an unprecedented scale: the so-called 
metabolic syndrome caused by type 2 diabe-
tes, hypertension, and changes in lifestyle.5 Th e 
early signs of a pandemic are visible: global fi g-
ures show a rapid rise in industrialized countries 
and an even more striking rise in low- and mid-
dle-income countries. In the US, the number of 
patients with type 2 diabetes will double between 
2000 and 2030 from 17 million to 34 million. In 
South Asia, the number will more than triple, 
from 23 million to 81 million.6 Worldwide, an 
increase from 154 million in 2000 to 360 mil-
lion in 2030 is expected to occur. Most of these 
patients will succumb to heart failure and stroke. 
No more than 10% will live to develop end-stage 
renal failure requiring renal replacement therapy, 
which in most cases will be unavailable or avail-
able only on a very limited scale.7
Early detection of type 2 diabetes, hyperten-
sion, and early kidney dysfunction — the main 
risk factors for chronic vascular disease — is 
the only viable option to contain this epidemic. 
Combined with eff ective low-cost therapy, it will 
be successful and should be high on the agenda 
of national governments and the World Health 
Organization.8–10
The kidney plays an important role in the 
pathogenesis of metabolic syndrome-associated 
chronic vascular disease as an important cause 
of hypertension, hypercalcemia, and anemia,11,12 
but it also provides us with a very eff ective disease 
marker.12,13 Th e appearance of trace amounts of 
albumen in the urine is one of the earliest signs 
of vascular injury in the metabolic syndrome; as a 
non-invasive and readily available procedure, uri-
nalysis for albuminuria can be the cost-eff ective 
cornerstone of early-detection health programs, 
as evidenced by a number of studies in high- and 
low-income countries.8,14,15
Over the past decade, members of the ISN have 
invested much energy and most of the Society’s 
fi nancial resources in ever growing global out-
reach programs. Off ering time on a voluntary 
basis, they have traveled far and wide to provide 
colleagues in countries in need with medical edu-
cation, including new insights in science and renal 
care.16,17 Site visits to countries such as Bolivia, 
Nepal, and Tanzania are followed up with regu-
lar continuing medical education conferences, 
senior scholar visits, and training opportunities 
for young fellows. Th e ISN has supported train-
ing of 389 fellows from 41 developing countries 
in centers of excellence, mostly in high-income 
countries. Oft en these fellows develop into local 
leaders in internal medicine and nephrology, 
contributing locally as well as to the international 
community.18
In 2004 and 2005 only, over 300 nephrologists 
contributed on behalf of the ISN to 125 national 
meetings worldwide. Most of this effort was 
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carried by established senior clinical nephrologists, giving lec-
tures, workshops, and meet-the-professor sessions. Similarly 
important, however, is the involvement of young colleagues, 
from both the clinical and the basic-scientifi c fi eld, as they will 
ignite enthusiasm among the young MDs, nephrologists, and 
scientists in the developing world. Young nephrologists from 
the industrialized world can provide inspiring examples for their 
counterparts in lower-income countries, as much as they can 
become intrigued themselves by the challenges that arise in a 
diff erent society with other patterns of disease and other priori-
ties. Th e ISN therefore calls upon all young MDs and scientists 
involved in the study of the kidney and in treatment of renal 
disease to join the Society, to participate in its programs, and 
thus to contribute as nephrologists sans frontières to equity in 
education, science, and renal care worldwide. You can do so by 
going to www.isn-online.org or by sending mail to me as coor-
dinator of ISN’s global outreach programs. Th e new editor of KI 
and I have decided to establish a dedicated section in the jour-
nal entitled Nephrologists sans Frontières, for which we invite 
contributions from all over the world. Th ese editorials should 
present discussions of phenomena in renal science and medicine 
at a local level (events, meetings, projects, personal stories) that 
the authors think will arouse the interest of a global audience.
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